Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Restructuring Costs (2016 - 2018)

Cardiff Oncology's Restructuring Costs history spans 3 years, with the latest figure at $421351.0 for Q3 2018.

  • For Q3 2018, Restructuring Costs rose 2733.77% year-over-year to $421351.0; the TTM value through Dec 2019 reached $421351.0, down 36.61%, while the annual FY2018 figure was $664686.0, 69.43% down from the prior year.
  • Restructuring Costs for Q3 2018 was $421351.0 at Cardiff Oncology, up from $243335.0 in the prior quarter.
  • Across five years, Restructuring Costs topped out at $1.7 million in Q1 2017 and bottomed at -$15998.0 in Q3 2017.
  • The 3-year median for Restructuring Costs is $421351.0 (2018), against an average of $518482.1.
  • The largest annual shift saw Restructuring Costs plummeted 40.0% in 2017 before it soared 6493.46% in 2018.
  • A 3-year view of Restructuring Costs shows it stood at $790438.0 in 2016, then tumbled by 40.0% to $474251.0 in 2017, then decreased by 11.15% to $421351.0 in 2018.
  • Per Business Quant, the three most recent readings for CRDF's Restructuring Costs are $421351.0 (Q3 2018), $243335.0 (Q2 2018), and $474251.0 (Q4 2017).